Auvelity

Product

Last mentioned: Jul 7, 2026

Share

Across the most recent 2 stories covering Auvelity — 100% neutral sentiment, averaging 5/10 impact.

This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived. See something wrong on this page? Report a data issue.

Timeline

  1. Moderna flu vaccine PDUFA date

    FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.

  2. Axsome full-year 2025 results

    Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.

  3. Revolution Medicines mid-2025 data readout

    RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.

Stories mentioning Auvelity 2